Alnylam Pharmaceuticals

Yahoo Finance • 2 days ago

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 48%?

Key Insights The projected fair value for Alnylam Pharmaceuticals is US$882 based on 2 Stage Free Cash Flow to Equity Alnylam Pharmaceuticals' US$457 share price signals that it might be 48% undervalued Analyst price target for ALNY is US... Full story

Yahoo Finance • 3 days ago

Dow Jones Futures: Bullish Market Pause; Palantir, Netflix, Oracle Right At Buy Points

The stock market rally paused at record highs. Palantir, Netflix and Oracle lead several stocks right around buy points. Continue Reading View Comments... Full story

Yahoo Finance • 10 days ago

Alnylam yanks Amvuttra TV ad following FDA letter - report

[View of Alnylam Pharmaceuticals company office facade with logo signs, Biotechnology industry] Veronique D/iStock Editorial via Getty Images Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) has pulled a televi... Full story

Yahoo Finance • 10 days ago

Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Wealth Enhancement Advisory Services LLC trimmed its position in Alnylam Pharmaceuticals, In... Full story

Yahoo Finance • 11 days ago

3 Stocks That May Be Trading Below Estimated Fair Value

As the U.S. stock market navigates through a government shutdown and unexpected private-sector job losses, major indices like the Nasdaq and S&P 500 continue to show resilience, with recent gains bringing them near record highs. In this fl... Full story

Yahoo Finance • 11 days ago

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

- Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment - - Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension with Either Establish... Full story

Yahoo Finance • 12 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interferenc... Full story

Yahoo Finance • 14 days ago

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – − Additional Analyses Reinforce Vutrisiran’s Safety and Eff... Full story

Yahoo Finance • 17 days ago

Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock?

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story

Yahoo Finance • 17 days ago

Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth?

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees... Full story

Yahoo Finance • 20 days ago

Discover 3 Stocks That Might Be Trading Below Their Estimated Fair Value

As U.S. stock indexes reach new highs, with the S&P 500 and Nasdaq posting their third consecutive week of gains, investors are increasingly focused on identifying opportunities that might be trading below their estimated fair value. In th... Full story

Yahoo Finance • 21 days ago

Jefferies sees broad equity opportunities beyond tech leaders

[Wall Street in New York City] JaysonPhotography/iStock via Getty Images With the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) up 13% year-to-date but gains concentrated in a narrow group of large-cap technology names, Jefferie... Full story

Yahoo Finance • 24 days ago

Alnylam Pharmaceuticals Insiders Sold US$12m Of Shares Suggesting Hesitancy

Many Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying is usually... Full story

Yahoo Finance • 27 days ago

Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This mome... Full story

Yahoo Finance • 29 days ago

Will Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative?

In early September 2025, Alnylam Pharmaceuticals announced and completed a US$575 million convertible zero coupon senior unsecured note offering due September 2028 and presented extensive long-term data from the HELIOS-B Phase 3 study of A... Full story

Yahoo Finance • last month

Guru Fundamental Report for ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This mome... Full story

Yahoo Finance • last month

Top 20 biopharma market caps fall 5.7% amid industry challenges

The biopharmaceutical industry faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures in the US. As a result, the top 20 global biopharmaceutical companies have reported a downturn of 5.7% in their combi... Full story

Yahoo Finance • last month

Alnylam prices $575M convertible senior notes

* Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) priced [https://seekingalpha.com/pr/20227268-alnylam-announces-pricing-of-upsized-offering-of-575-million-convertible-senior-notes] its previously announced p... Full story

Yahoo Finance • last month

Alnylam announces proposed offering of $500M convertible senior notes

* Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. * The notes will be senior, unsecured obli... Full story

Yahoo Finance • last month

RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence

AUSTIN, Texas and TOKYO, Sept. 4, 2025 /PRNewswire/ -- According to DataM Intelligence, the RNAi technology market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected to reach US$ 6.63 Billion by 2033, growi... Full story